Congress must reject cuts to PEPFAR, which has supported H.I.V. treatment and prevention worldwide for more than 20 years.

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

WHO has officially recommended twice-yearly injectable lenacapavir for HIV prevention, marking a major shift in global HIV ...

The World Health Organisation (WHO) has for the first time recommended the use of injectable lenacapavir (LEN) as a ...

The elimination of the latent viral reservoir remains the main barrier in the quest for a cure for people with HIV (PWH). The administration of latency reversal agents (LRA) at antiretroviral ...

A GNA feature by Laudia Sawer   Tema, July 12, GNA  -  On any ordinary morning, Maame Esi, an HIV mentor mother, stands among other mothers at the antenatal clinic ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...

The halt to US foreign aid is a "ticking time bomb" that could reverse decades of hard-fought gains in the fight against AIDS ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The risk for MACEs was higher among patients with HIV infection receiving abacavir- vs tenofovir-based ART regimens.